Precision Medicine in Oncology®

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

Located in Tampa, Florida, Moffitt Cancer Center enjoys a reputation as one of the world's most sophisticated cancer centers.

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Many targeted therapies are associated with dermatologic side effects; the monitoring and treating of these side effects should be done on an individual patient basis.

Dr. Neil Spector, from Duke Cancer Institute, Emphasizes the Importance of Studying Tumor Microenvironments

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Leonard M. Neckers, PhD, has been studying the role of the molecular chaperone Hsp90 in signal transduction and the translational development of Hsp90-targeted anticancer agents for two decades.

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

The USC Norris Comprehensive Cancer Center and Hospital has long enjoyed a national reputation as a leading resource for cancer research, treatment, prevention, and education.

Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.